-
Federal Circuit dismisses ParkerVision appeal against Qualcomm: Rule 54(b) does not allow partial final judgment on some claims of one patent
Read more: Federal Circuit dismisses ParkerVision appeal against Qualcomm: Rule 54(b) does not allow partial final judgment on some claims of one patentThe Federal Circuit has held that a patent is a single cause of action, so judgments on receiver claims cannot be appealed while transmitter claims remain pending. ParkerVision’s 15 years of litigation have returned to Florida.
-
UPC Court of Appeal establishes need for conditional appeals to keep conditional revocation counterclaims alive in ParTec v. Nvidia
Read more: UPC Court of Appeal establishes need for conditional appeals to keep conditional revocation counterclaims alive in ParTec v. NvidiaWhile the CoA has granted a motion for Nvidia to reinstate its right to file an appeal in a case against ParTec, it warned that Nvidia should have brought a conditional appeal to keep its conditional revocation counterclaim alive in the event that the CoA reverses a non-infringement finding made by the UPC’s Munich LD…
-
Nvidia sued in Eastern District of Texas by PAE holding data center, networking patents originally owned by Avaya
Read more: Nvidia sued in Eastern District of Texas by PAE holding data center, networking patents originally owned by AvayaPulseLink Systems is also enforcing former Avaya patents against Hewlett Packard Enterprise and Zoom.
-
Netlist adds new ITC complaint against Micron, Broadcom, Google, and Nvidia; “intends to rely on… Samsung” to prove domestic industry
Read more: Netlist adds new ITC complaint against Micron, Broadcom, Google, and Nvidia; “intends to rely on… Samsung” to prove domestic industryAfter settling with Netlist last month, Samsung agreed to provide “certain information… to use in future ITC actions against third parties”.
-
Novo Nordisk signs GLP-1 licensing agreement with China’s Hengrui Pharma
Read more: Novo Nordisk signs GLP-1 licensing agreement with China’s Hengrui PharmaNovo Nordisk and Hengrui Pharma’s agreement, subject to antitrust approval, will allow Novo to obtain exclusive rights to develop, manufacture, and commercialize HRS-1596 globally, excluding mainland China, Hong Kong, Macao, and Taiwan.
-
Adeia appoints former Arm executive as CEO, with licensing into new verticals at the top of her to-do list
Read more: Adeia appoints former Arm executive as CEO, with licensing into new verticals at the top of her to-do listDipti Vachani, who also worked at Intel and Texas Instruments, was previously focused on semiconductor licensing for the automotive and IoT segments.
-
Via annual Bridge Summit to focus on AI licensing
Read more: Via annual Bridge Summit to focus on AI licensingVia Licensing Alliance’s fourth-ever annual Bridge Summit, due to take place next week, will feature AI infrastructure and data center licensing discussions throughout its conference, as well as licensor meetings dedicated to its newly launched DRAM pool.
-
Roborock turns the tables on Ecovacs: first UPC suit escalates patent war across U.S., Europe, China
Read more: Roborock turns the tables on Ecovacs: first UPC suit escalates patent war across U.S., Europe, ChinaRoborock has filed its first UPC infringement suit against Ecovacs, turning their UPC dispute into a two-way fight. Following two reported German injunction wins and the reversal of Ecovacs’ inspection order, the new Munich action escalates a patent battle between Chinese rivals spanning China, Europe and the U.S.
Follow Us
Latest Articles
- Federal Circuit dismisses ParkerVision appeal against Qualcomm: Rule 54(b) does not allow partial final judgment on some claims of one patent
- UPC Court of Appeal establishes need for conditional appeals to keep conditional revocation counterclaims alive in ParTec v. Nvidia
- Nvidia sued in Eastern District of Texas by PAE holding data center, networking patents originally owned by Avaya
- Netlist adds new ITC complaint against Micron, Broadcom, Google, and Nvidia; “intends to rely on… Samsung” to prove domestic industry
- Novo Nordisk signs GLP-1 licensing agreement with China’s Hengrui Pharma